Reduction inflammatory manifestations dry and giperkeraticheskih dermatoses sensitive to therapy with corticosteroids, including – psoriasis, chronic atopic dermatitis, neurodermatitis (chronic simple stripping), lichen planus, eczema (including nummular eczema, eczema of the hands, eczematous dermatitis ) dyshydrosis, seborrheic dermatitis of the scalp, ichthyosis trenbolone acetate stack with and ichthyosiform other states.
– Hypersensitivity to any component of the drug.
– Children under 2 years of age.
– Pregnancy (long-term treatment at high doses).
– Rosacea, perioral dermatitis.
– Bacterial, viral or fungal skin infection (pyoderma , syphilis, tuberculosis, skin, Herpes simplex, chicken pox, Herpes zoster, actinomycosis, blastomycosis, sporotrichosis).
– Trophic ulcers in chronic venous insufficiency.
– Tumors of skin (skin cancer, mole, atheroma, epithelioma, melanoma, hemangioma, xanthoma, sarcoma).
– post-vaccination skin reactions.
Children under 12 years old, liver failure, long-term treatment, use over large areas of the skin, the use of occlusive dressings.
Use during pregnancy and lactation
Due to the fact that the safety of local corticosteroids in pregnant women has not been established, the purpose of this class of drugs during pregnancy is justified only if the potential benefit to the mother outweighs the potential risk to the fetus.
Drugs of this class do not should be used during pregnancy in high doses or for a long time.
So how far not clear whether the level of systemic absorption of local corticosteroids for the appearance of detectable concentrations in mother’s milk is sufficient, should be discontinued or breastfeeding, or use of the drug, taking into account the extent to which its use necessary for the mother.
Dosage and administration:
Outwardly. Apply a thin layer 2 times a day – morning and night, completely covering the affected skin. In some patients, the supporting effect can be achieved less frequent applications. Children aged 2 to 12 years – to put a thin layer on a small area of skin 1 or 2 times a day for no more than 1 week.
Adverse events that occurred with topical corticosteroids, included burning, itching, irritation, dryness, folliculitis, hypertrichosis, akne- like rash, hypopigmentation, perioral dermatitis, allergic contact dermatitis, purpura, telangiectasia, local hirsutism, dermatitis . The following events occurred more frequently in the application of occlusive dressings:. Maceration of the skin, secondary infection, skin atrophy, striae and miliaria
When adverse reactions are trenbolone acetate stack with not included in these instructions, you should consult a doctor.
Overdose symptoms. Prolonged use of local corticosteroids in large doses can cause suppression of pituitary-adrenal axis, leading to secondary adrenal insufficiency features and phenomena of Cushing, including Cushing’s syndrome. Prolonged use of high doses of drugs containing salicylic acid may lead to poisoning of the salicylic acid. Treatment. Results appropriate symptomatic treatment. Acute symptoms of Cushing’s usually reversible. If necessary – correction of electrolyte imbalance. In case of chronic toxicity recommended phasing out of GCS. In case of overdose symptomatic treatment also salicylates. Measures should be taken for the speedy elimination of salicylates from the body, such as the ingestion of sodium bicarbonate (alkalinization of urine) and forcing diuresis.
Interaction with other drugs
of any drug interaction Diprosalik ointment with other drugs have been reported.
If during treatment with the drug developed hypersensitise or irritation, treatment should be discontinued. Should appoint the appropriate treatment in case of infection joining. When topically applied corticosteroids, especially in children, may experience side effects that are typical of systemic corticosteroids, including inhibition of the function of the hypothalamic-pituitary-adrenal system.
Systemic absorption of corticosteroids and salicylic acid in their local application will be higher when using occlusive dressings, as well as, if undergo extensive treatment of the body surface.
With long-term treatment of drug recommended its abolition gradually.
The drug is not intended for use in ophthalmology. Avoid contact with eyes and mucous membranes.
The use in children under the age of 12 years is possible only under medical supervision. Children are more than adults are at risk of suppression of the hypothalamic-pituitary-adrenal system in the application of local corticosteroids due to the higher value ratio of the area to its mass surface of the body and, consequently, an increased absorption of the drug.
There were reports of decreasing function of the hypothalamic-pituitary-adrenal axis , Cushing’s syndrome, growth retardation, insufficient body weight gain and increased intracranial pressure in children treated with corticosteroids for topical use. Inhibition of the function of the hypothalamic-pituitary-adrenal axis in children is determined by the low level of cortisol in plasma and the lack of response to stimulation by adrenocorticotropic hormone. Increased intracranial pressure manifested bulging fontanelle, headaches, bilateral papilledema.
ointment for external use. 30 g in aluminum tubes, treated with epoxy varnish and closing the membrane and a plastic screw-cap with a punch to rupture membrane. According trenbolone acetate stack with to one tube, together with instructions for use in a carton box.
Store in a place inaccessible to children at temperature not above 25 o C. The
Do not use beyond the expiration date.
Conditions of supply of pharmacies
without a prescription.